Antifungal medication could provide asthma relief for 150,000 UK sufferers
A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy. Botulism is caused by a bacterium, Clostridium botulinum, which produces toxins that cause paralysis and often death, as the muscles that control breathing fail. Out
Full Post: New nasal spray vaccine shown to be effective against botulism
Up to 150,000 people suffering from severe asthma in the UK could benefit from taking antifungal medication already available from pharmacists, new research has found.
University of Manchester scientists found that pills used to treat everyday fungal infections greatly improved symptoms of asthma in those patients that had an allergic reaction to one or more fungi.
The study, carried out at four hospitals in northwest England and published in the American Journal of Respiratory and Critical Care Medicine , is the first to show that antifungal therapy can improve the symptoms of those who suffer from severe asthma.
The researchers compared the oral antifungal drug itraconazole with a placebo over eight months and found that nearly 60% of patients taking the drug showed significant improvement in their symptoms.
“Only patients with a positive skin or blood test for fungal allergy were included in the study,” said Professor David Denning, who is based at the University Hospital of South Manchester.
“Severe asthma affects between five and 10% of adult asthmatics and probably 25 to 50% of these patients showed allergy to one or more fungi. Since about 60% of those treated benefited from the treatment, we believe that antifungal therapy may be helpful in as many as 150,000 adults with asthma in the UK.”
The clinical study of 58 patients at the University Hospital of South Manchester, Salford Royal, Royal Preston and North Manchester General hospitals showed statistically significant improvements in a validated quality of life score. Patients’ asthma and nasal symptoms deteriorated within four months of stopping therapy.
Dr Robert Niven, from The University of Manchester and the University Hospital of South Manchester, said: “This pioneering study indicates that fungal allergy is important in some patients with severe asthma, and that oral antifungal therapy is worth trying in some difficult-to-treat patients. Clearly itraconazole will not suit everyone, and is not always helpful, but, when it is, the effect is dramatic.”
Dr Ronan O’Driscoll, at Salford Royal Hospital, added: “It’s good news for patients with severe asthma to have an existing anti-fungal drug recognised as having benefits for asthma patients with fungal allergy. We found that many patients were only picked up by extensive skin and blood test screening for fungal allergy, so a change of clinical practice will be required to identify all the patients who might respond to itraconazole.”
The effectiveness of voriconazole in combating fungal infections has been confirmed by a new study to be featured in the International Journal of Antimicrobial Agents, published by Elsevier. Fungal infections can kill people with weakened immune systems, which can be caused by AIDS, cancer treatment or organ replacement, and the research reinforces earlier findings
Full Post: Voriconazole effective in combating fungal infections
RHEI Pharmaceuticals, Inc. has announced that the final clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system, has been initiated in China. This will be the last clinical trial conducted for submission of the New Drug Application (NDA) to the State Food and Drug Administration (SFDA) in China.
Full Post: RHEI Pharmaceuticals starts final trial of Tibozole in China
Death from asthma is uncommon. Available mortality statistics for the United States indicate a death rate of approximately 0.3 per 100,000 persons. The available information on the clinical course of asthma suggests that somewhere between 50 to 80 percent of all patients can expect to have a reasonably good prognosis, particularly those whose disease is mild
Full Post: Asthma
Experts in the U.S. say food allergies are on the rise and although strict avoidance is currently the only treatment, new effective therapies are currently being developed. According to experts at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Seattle, research shows that food allergies are increasing - especially
Full Post: Food allergies are on the rise but effective treatment in the pipeline
Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids. The study further defines the safety profile of Xolair in this patient population.
Full Post: Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid